CA
TRVI icon

Clearstead Advisors’s Trevi Therapeutics TRVI Stock Holding History

Clearstead Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39
Closed -$357 – 3245
2025
Q3 		$357 Buy
+39
New +$292 ﹤0.01% 2783

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Clearstead Advisors's TRVI Position: Q4 2025 in Review

Clearstead Advisors sold out of Trevi Therapeutics (TRVI) in Q4 2025, closing a stake of 39 shares — an estimated $357 sold.

Clearstead Advisors first reported a position in TRVI in Q3 2025 and held it in 1 quarter. The position peaked at $357 in Q3 2025. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • Clearstead Advisors reported no remaining Trevi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 39 Trevi Therapeutics shares in Q4 2025, an estimated $357.
  • Clearstead Advisors first reported a position in Trevi Therapeutics in Q3 2025 and held it in 1 quarter.
  • Clearstead Advisors's Trevi Therapeutics position peaked at $357 in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.